Markets

BioMarin (BMRN) Looks Good: Stock Adds 8.8% in Session

BioMarin Pharmaceutical Inc. ( BMRN ) was a big mover last session with its shares rising nearly 9% on the day. The upside came on the company's announcement that the Patent Trial and Appeal Board (PTAB) has issued a decision in favor of BioMarin's claims to the use of exon 51 antisense oligonucleotides to treat Duchenne muscular dystrophy. This development led to far more shares changing hands yesterday than in a normal session. The move reverses the recent downtrend of the company, as the stock has lost over 15% in the past one month time frame.

This pharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Yesterday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

BioMarin currently has a Zacks Rank #3 (Hold) and its Earnings ESP is positive.

Investors interested in the biomedical industry may, however, consider VIVUS Inc. ( VVUS ) that carries a Zacks Rank #1 (Strong Buy).

Is BMRN going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BIOMARIN PHARMA (BMRN): Free Stock Analysis Report

VIVUS INC (VVUS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMRN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More